REPORTED BY
youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS MD, PH.D., C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., WALTER F. WRENN III., MD., JULIE KILLINGWORTH, STEVE ARIENS RPH., LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., LEROY BAYLOR, JAY K. JOSHI MD., MBA, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
VICTORY FOR PAIN-CARE IN AMERICA
January 4, 2023, was one of the greatest in Pain Healthcare, as a Detroit Federal Jury found, after nearly eight years of torture by DOJ-DEA, Lesly Pompy MD., not guilty on 34 separate charges of healthcare fraud and drug trafficking.
This verdict occurring once again in Detroit represents another massive defeat of the United States Drug Enforcement Administration (DEA). The verdict also more than highlights their abuse in attempting to redefine medicine, something they are not authorized to do as a government agency by Congress. Thus the DEA has become an authoritarian movement that seeks power by any means necessary.
As further outlined in previous articles, the federal prosecutor had gathered a number of Dr. Pompy’s current & former employees and a number of pts that the prosecutor believed would testify on how poorly Dr. Pompy practiced medicine.
However, prosecution witness after witness testified how Dr. Pompy was doing everything “by the book.” AUSA Wayne Pratt grew angry and outright attempted to manipulate the testimony of his own witnesses. especially after Diana Knight, a witness for the prosecution, stated, “proper billing occurred and that nothing was fraudulent.” Ms. Diana Knight was Dr. Pompy’s medical office biller, and her testimony was strongly in Pompy’s favor.
- What did the prosecuting attorney promise all these witnesses?
- Immunity from being prosecuted themselves for being “active participants” in the alleged “pill mill” they had claim Dr. Pompy was running?
Prosecutors and the DEA have learned when facts don’t support the charges, one just fabricates the facts. Thus the phrase garbage in is garbage out, or the legal term false en Uno false en omnibus is applicable.
It would have been expected a higher level of scientific accuracy and integrity from an agency such as the DEA entrusted to protect citizens’ health and welfare.
“…Without the discipline of good science, nontransparent implementation produces poor public outcomes. These outcomes are pressed into service in the field, offer no benefit, and harm physicians, pharmacies, patients, and public policy at large…”
NOT GUILTY ON ALL COUNTS
THE AMERICAN MEDICAL ASSOCIATION CONCERNS
The American Medical Association (AMA) has noted these abuses in its June 16, 2020, letter to Deborah Dowell, MD, MPH Chief Medical Officer National Center for Injury Prevention and Control U.S. Centers for Disease Control and Prevention 4770 Buford Highway, NE Atlanta, GA 30341 which stated
“We are concerned that such a careful approach to identifying the precise combination of pharmacologic options could be flagged on a prescription drug monitoring program as indications wrongly interpreted as so-called “doctor shopping” and cause the patient to be inappropriately questioned by a pharmacist.
The AMA strongly supports a pharmacist carrying out his or her corresponding responsibility under state and federal law, but the past few years are rife with examples of patients facing what amounts to interrogations at the pharmacy counter as well as denials of legitimate medication.
URGENT!!! HELP AND SUPPORT NORMAN CLEMENT vs. DEA IN US SUPREME COURT CASE NO: 22-6000
OR SEND
$100 $250, $500 DOLLARS SEND
TO ZELLE: 3135103378 OR CASH APP: $docnorm
ADVOCATES JAY JOSHI MD AND CLAUDIA MERANDI
Pain is a complex and subjective experience initiated by an unpleasant (or noxious) stimulus associated with actual or potential tissue damage. Pain is a primitive response that motivates us to withdraw from the source that is causing the pain and protect the body from further damage. The unpleasant feeling associated with pain is also stored in our memory so that we can avoid similar situations in the future. While seemingly intimidating, its understanding is not all that difficult.
DEA ABUSE BASED ON AN INVALID GUIDELINE AND CONCEPT
Overprescribing has no definition, is not a medical term, and has not been proven that substance exposure alters any aspect of the “opioid crisis.” In fact, patients on long-term opiate therapy for pain stabilization are the least likely to overdose.
Richard Lawhern PH.D.“Morphine Milligram Equivalent Daily Dose (MMEDD) is not a useful measure in defining limits on opioid dosage, and as such, it has been repudiated by the American Medical Association(AMA). Its major utility is as a rough guide to the clinician in making a safe transition from one opioid to another.”
THE RUAN DECISION PROOF BEYOND A REASONABLE DOUBT
In a legal column published by U.S. Pharmacist, Hinshaw partner Michael Dowell discussed the impact of the U.S. Supreme Court’s decision in the consolidated case Ruan v. United States and Kahn v. United States.
The Ruan decision ruled that the Drug Enforcement Administration (DEA) must prove beyond a reasonable doubt that a prescriber knowingly or intentionally issued a prescription that they knew or intended was not for a legitimate medical purpose in order to subject that physician to criminal penalties under the Controlled Substances Act (CSA).
Dowell provides a thorough outline of the case, which he describes as having “significant implications for all persons and entities subject to the CSA, including pharmacists and pharmacies who are subject to a ‘corresponding responsibility only to fill lawful prescriptions issued for a legitimate medical purpose.”
Dowell addressed the decision’s impact on pharmacies and DEA enforcement actions:
With the added mens rea element to prove, DEA enforcement actions against physicians, pharmacies, pharmacists, wholesale drug distributors, pharmaceutical manufacturers, and other controlled-substances prescribers for wrongfully distributing or dispensing opioids and other controlled substances under various fact patterns may be less likely to occur and/or less likely to result in convictions.
He added that the decision increases the DEA’s elements-of-proof threshold for CSA violation convictions but is not expected to be a significant obstacle to future DEA enforcement actions.
Read the full article on the U.S. Pharmacist website
FOR NOW, YOU ARE WITHIN
THE NORMS
URGENT!!! HELP AND SUPPORT NORMAN CLEMENT vs. DEA IN US SUPREME COURT CASE NO: 22-6000
OR SEND
$100 $250, $500 DOLLARS SEND
TO ZELLE: 3135103378 OR CASH APP: $docnorm
LOW HANGING FRUIT
